Zoom webinar – Counting cells with microcarriers
Webinar: Counting cells with microcarriers
Duration: 30 minutes with 15 minutes Q&A
Join Pedro, the author of the groundbreaking study on the scalable manufacturing of gene-modified hMSCs, as he delves deep into the world of adherent cell manufacturing to microcarriers. Discover why traditional manual counting methods might be holding back your research and how automated cell counts are revolutionizing both GMP manufacturing and research labs.
In this webinar, we will discuss the following:
- The drawbacks of manual cell counting.
- Benefits of automated cell counts for research & GMP manufacturing.
Key findings from Pedro’s studies:
- Optimal incubation times.
- Equipment linearity across concentrations.
- Real-world manufacturing scenarios.
- Versatility across different microcarriers.
Speaker – Dr. Pedro Azevedo Da Silva Couto
Postdoctoral Research Fellow· University College London (UCL)
Pedro is a postdoctoral research fellow at the University College London (UCL) in the UK. His current project is focused on establishing scalable manufacturing platforms for non-viral CAR-T products using electroporation and mechanoporation. Prior, Pedro was a PhD student in Prof. Qasim Rafiq’s lab where he conducted research focused on identifying differences between hMSCs isolated from different donors as well as exploiting the manufacturing implication of those differences.
During his PhD Pedro worked with hMSCs, microcarriers and lentiviral vectors to deliver clinically relevant transgenes towards the manufacturing of ex vivo gene therapy products. During this period Pedro initiated multiple collaborative partners including clinicians, pharmaceutical and technology companies operating the cell and gene therapy manufacturing space.
Host – Carl Aston
Field Application Scientist·ChemoMetec A/S
His journey began with a passion for science, leading him to successful completetion of a PhD in Molecular Microbiology from the University of Nottingham focussing on the development of a mucosal vaccine platform against the spore-forming bacteria C. difficile. Afterwards working as a scientist at QIAGEN Manchester with qPCR diagnostic assays and latest as a Field Application Scientist at ChemoMetec.
Carl’s passion for science lead him to successfully complete a PhD at the University of Nottingham, focussing on the development of a mucosal vaccine platform against the enteric, spore-forming bacteria C. difficile utilising non-pathogenic strains as vehicles for novel vaccine candidates. Post-PhD, he worked as a Scientist at QIAGEN Manchester developing qPCR-based assays as part of their Molecular Assay Development department. Now Carl is one of ChemoMetec’s Field Application Scientists providing technical scientific support in the forms of troubleshooting and training, as well as the installation and servicing of NucleoCounters
0 Comments